Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SYK 
Stryker Corporation (SYK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: SYK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
32 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $429.26
1 Year Target Price $429.26
| 13 | Strong Buy |
| 9 | Buy |
| 9 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.08% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 139.51B USD | Price to earnings Ratio 48.33 | 1Y Target Price 429.26 |
Price to earnings Ratio 48.33 | 1Y Target Price 429.26 | ||
Volume (30-day avg) 32 | Beta 0.95 | 52 Weeks Range 327.71 - 403.95 | Updated Date 10/14/2025 |
52 Weeks Range 327.71 - 403.95 | Updated Date 10/14/2025 | ||
Dividends yield (FY) 0.91% | Basic EPS (TTM) 7.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.25% | Operating Margin (TTM) 21.95% |
Management Effectiveness
Return on Assets (TTM) 7.74% | Return on Equity (TTM) 14.25% |
Valuation
Trailing PE 48.33 | Forward PE 24.39 | Enterprise Value 154193393987 | Price to Sales(TTM) 5.86 |
Enterprise Value 154193393987 | Price to Sales(TTM) 5.86 | ||
Enterprise Value to Revenue 6.47 | Enterprise Value to EBITDA 26.75 | Shares Outstanding 382307298 | Shares Floating 344600329 |
Shares Outstanding 382307298 | Shares Floating 344600329 | ||
Percent Insiders 5.36 | Percent Institutions 81.86 |
Upturn AI SWOT
Stryker Corporation
Company Overview
History and Background
Stryker Corporation was founded in 1941 by Dr. Homer Stryker, an orthopedic surgeon. Initially focused on developing medical products to improve patient outcomes, it has grown into a global leader in medical technology.
Core Business Areas
- MedSurg and Neurotechnology: This segment offers surgical equipment, navigation systems, endoscopic technologies, communications systems, and neurosurgical, neurovascular, and spinal devices.
- Orthopaedics and Spine: This segment focuses on implants used in hip, knee, shoulder, elbow, trauma, and spine surgeries.
Leadership and Structure
The current CEO is Kevin Lobo. Stryker operates with a divisional structure under a corporate umbrella, with each division managing its own product lines and sales.
Top Products and Market Share
Key Offerings
- Mako Robotic-Arm Assisted Surgery System: This robotic surgical system assists surgeons in performing knee and hip replacement surgeries. Stryker is the market leader in robotic-assisted joint replacement. Competitors include Zimmer Biomet (ROSA) and Smith & Nephew (CORI).
- Trauma and Extremities: Stryker offers a broad range of implants and instruments for fracture fixation and reconstruction of the upper and lower extremities. They have a significant market share in this segment and compete with DePuy Synthes (JNJ) and Zimmer Biomet (ZBH).
- Endoscopy: Stryker's endoscopy business produces visualization systems and devices used in minimally invasive surgery. They compete with Olympus and Karl Storz.
Market Dynamics
Industry Overview
The medical technology industry is characterized by innovation, regulatory oversight, and increasing demand driven by an aging population and technological advancements.
Positioning
Stryker is a market leader in several key segments, with a strong focus on innovation and acquisitions. Its size and global reach provide a competitive advantage.
Total Addressable Market (TAM)
The global medical device market is expected to reach approximately $600 billion by 2027. Stryker is well-positioned to capture a significant portion of this TAM due to its diverse product portfolio and strong market presence.
Upturn SWOT Analysis
Strengths
- Strong Brand Reputation
- Extensive Product Portfolio
- Global Distribution Network
- Focus on Innovation
- Proven Acquisition Strategy
Weaknesses
- High R&D Costs
- Dependence on Acquisitions for Growth
- Exposure to Regulatory Risks
- Premium Pricing May Limit Accessibility
Opportunities
- Expanding into Emerging Markets
- Developing New Robotic Surgical Technologies
- Acquiring Smaller Innovative Companies
- Growing Demand for Minimally Invasive Procedures
Threats
- Increased Competition
- Pricing Pressures from Healthcare Providers
- Changes in Reimbursement Policies
- Product Liability Lawsuits
Competitors and Market Share
Key Competitors
- ZBH
- JNJ
- BSX
Competitive Landscape
Stryker competes with a variety of large and small medical technology companies. Its competitive advantages include its strong brand, diverse product portfolio, and global reach. Disadvantages include higher pricing and dependence on acquisitions.
Major Acquisitions
Vocera Communications
- Year: 2022
- Acquisition Price (USD millions): 3090
- Strategic Rationale: Expanded Stryker's digital healthcare solutions and provided better communication for caregivers.
Growth Trajectory and Initiatives
Historical Growth: Stryker has experienced significant growth through organic initiatives and strategic acquisitions.
Future Projections: Analysts project continued revenue growth in the high single digits, driven by new product launches and increasing demand for medical technology.
Recent Initiatives: Recent strategic initiatives include the development of new robotic surgical platforms and expansion into emerging markets.
Summary
Stryker is a strong company with a leading position in the medical technology industry. Its diverse product portfolio and global reach provide a solid foundation for future growth. However, it must continue to innovate and manage pricing pressures to maintain its competitive advantage. Future acquisition integrations and macroeconomic conditions need monitoring.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Stryker Corporation Annual Reports
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stryker Corporation
Exchange NYSE | Headquaters Portage, MI, United States | ||
IPO Launch date 1988-02-01 | Chairman, CEO & President Mr. Kevin A. Lobo | ||
Sector Healthcare | Industry Medical Devices | Full time employees 53000 | Website https://www.stryker.com |
Full time employees 53000 | Website https://www.stryker.com | ||
Stryker Corporation operates as a medical technology company. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke, cranial, and maxillofacial and chest wall devices, as well as dural substitutes and sealants; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries; thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.